Research on malaria and the fight against it. Covers red-blood-cell inflammation, malaria resurgence, drug-resistant parasites, and mosquito-based control.
The incidence of malaria has fallen dramatically in The Gambia over the past five years, with significant decreases in malaria-positive slides and admissions. Improved measures to prevent malaria, including increased use of insecticide-treated bed nets and indoor residual spraying, are believed to be major contributors to this decline.
Between 1999-2007, malaria incidence and mortality declined significantly in The Gambia thanks to increased funding and targeted interventions for pregnant women and young children. Proportions of malaria-positive slides decreased by up to 82% and deaths attributed to malaria fell by 100% in some hospitals.
Data from Kenya shows a delay between decreased malaria transmission and mortality rates. The study found that when transmission is high, the disease burden falls mainly on small children, but when transmission decreases, the burden spreads throughout childhood, leading to an increased proportion of children with severe cerebral malaria.
A recent study found a remarkable 75% decrease in severe malaria deaths from 10.8 to 1.2 per 10,000 between 2015 and 2020 along the Kenyan coast. The decline is attributed to improved treatment, bednet usage, and mosquito breeding site management.
A team of ASU researchers will investigate the ecology, evolution, and genetic mysteries behind malaria and retroviral diseases in humans and nonhuman primates. The studies aim to understand malaria drug resistance and host shifts in parasites.
A $900,000 Google grant will aid the International Research Institute for Climate and Society in predicting disease outbreaks in Ethiopia, a high-risk area for malaria and meningitis. The project aims to develop disease-mapping tools using climate data and improve early-warning systems.
A new report highlights the urgent need to tackle pneumococcal disease, a leading cause of death among children under five. The UK All-Party Parliamentary Group recommends increasing vaccine availability and healthcare system strengthening in developing countries to reduce child mortality rates.
A new dispersible antimalarial tablet is as effective as crushed tablets, improving adherence and cure rates in children. The study found a higher day-28 cure rate and lower adverse events with the new tablet.
Researchers have deciphered the complete genetic sequence of Plasmodium vivax, the leading cause of relapsing malaria. The findings provide new insights into the biology of vivax malaria and may lead to new tools for prevention and treatment.
Researchers have discovered unique genes in the genome of Plasmodium vivax, a parasite responsible for 25% of global malaria cases. The findings could lead to the development of new drugs and vaccines against this debilitating disease.
The genome sequence of Plasmodium knowlesi has been defined, providing new research opportunities for comparisons with P. vivax. Establishing similarities and differences between the parasites' genomes will assist in the selection of genetic targets for vaccine and drug development.
The genome of Plasmodium knowlesi, a mosquito-human malaria parasite, has been decoded, revealing unique genetic features that enable it to evade host immune systems. The study found that the parasite's genes are scattered throughout its genome, unlike other malaria parasites, and that it uses molecular mimicry to survive and propagate.
The study reveals that Plasmodium vivax has a distinct genome with only 150 genes, raising new questions about its biology and infection mechanisms. Alternative routes of infection have been identified, highlighting the need for further research to combat this parasite.
Researchers from NYU Langone Medical Center have successfully decoded the genome of Plasmodium vivax, a species responsible for up to 40% of annual malaria infections worldwide. The breakthrough could lead to the development of new treatments and vaccines against this deadly disease.
The 'Rolling Back Malaria' partnership has announced a comprehensive plan to control and eradicate malaria, targeting short-term reduction of mortality and morbidity by half by 2010 and long-term elimination of transmission. The plan is estimated to save 4.2 million lives in Africa, but requires $62 billion in funding by 2020.
Researchers have developed a way to produce an antimalarial compound cheaply, which could make treating malaria less expensive. This process could also lead to the discovery of new antibiotics as bacteria are harnessed to produce compounds with antibiotic properties.
According to a new analysis, NTDs as a group may have surpassed HIV/AIDS, tuberculosis, and malaria as the most prevalent infectious diseases in Latin America and the Caribbean. The region is home to approximately 200 million people affected by NTDs, including intestinal worm infections and Chagas disease.
The University of Queensland's new center, the Pacific Malaria Initiative Support Centre (PacMISC), is part of a global effort to eliminate malaria in low and middle-income countries. PacMISC will focus on Vanuatu and Solomon Islands, providing flexible assistance to national malaria control programs.
A 'dodgy dossier' of faulty intelligence and tactics contributed to the failure of the war against malaria in tropical countries. Dr. Colin Sutherland explains that a one-size-fits-all approach was miscalculated, and the parasite is now at its strongest in these regions.
Dr. Joseph DeRisi receives the Heinz Award for his pioneering work in viral detection platforms, including the ViroChip that detects new viruses and characterizes malaria parasites' life cycles. His open access approach to science enables free sharing of research and software.
Scientists suggest using multiple first-line therapies to treat malaria, cutting death rates and delaying drug resistance. The approach involves distributing different drugs to patients, allowing them to choose from a variety of options.
Researchers at Johns Hopkins Bloomberg School of Public Health identified a new virus, AgDNV, infecting Anopheles gambiae mosquitoes. The virus, a densovirus, could be used to pass on genetic information to control malaria transmission.
The University of Texas at San Antonio has been awarded a five-year, $9 million grant from the National Institutes of Health to support 10 faculty research projects. The funding will increase participation of individuals from minority or underrepresented groups in scientific research.
Platelet activation plays a key role in the development of cerebral malaria by triggering an immune response and obstructing blood vessels in the brain. Researchers found that treating mice with aspirin or Plavix improved survival rates when administered soon after infection.
A study has identified a specific region of the PfEMP1 protein as crucial for attaching to placental walls, which could lead to new drug targets to prevent malaria-related complications during pregnancy. Researchers hope that mimicking this binding domain with pharmaceuticals may help develop immunity in women living in endemic regions.
Médecins Sans Frontières (MSF) enrolled over 12,000 patients in 43 studies across 18 countries, providing extensive evidence on malaria medication efficacy. These studies played a crucial role in shaping treatment policies in conflict-affected regions.
A study published in Pediatrics found that cerebral malaria is related to long-term cognitive impairment in African children. At six months and two years after the initial episode, 21% and 26% of children with cerebral malaria showed significant cognitive impairment compared to their healthy peers.
Caltech bioengineers create a super-compact high-resolution microscope, small enough to fit on a finger tip, operating without lenses. The optofluidic microscope can be used in the field to analyze blood samples and mass-produced for $10.
Research finds that international malaria financing is insufficient to achieve the goal of halving the global burden of malaria by 2015. Funding commitments are largely tied to stable P. falciparum risk, leaving countries with high but low-risk populations poorly supported.
According to a report by Professor Bob Snow, funding for malaria control is severely inadequate, with many countries receiving less than $0.50 per person at risk. The research highlights regional disparities and shortfalls in funding, particularly in South East Asia and the Western Pacific regions.
Researchers discovered high levels of ciprofloxacin resistance in Escherichia coli among Amerindians from Guyanese rainforest, despite no reported use of fluoroquinolone antibiotics. Chloroquine treatment for malaria may contribute to bacterial resistance.
A new study found that providing preventive treatment for malaria significantly improves the cognitive ability of schoolchildren and reduces rates of anaemia, while also revealing a link between malaria infection and reduced attention in class. IPT dramatically reduced the occurrence of malaria infection in schoolchildren.
Researchers found that intermittent preventive treatment (IPT) for malaria lowers anaemia prevalence and improves classroom attention in children aged 5-18 years in Western Kenya. The IPT reduced the occurrence of malaria infection by half and lowered anaemia rates among children.
Researchers have identified eight new proteins that transport the Plasmodium falciparum parasite's 'glue' to the surface of infected red blood cells. Removing one of these proteins prevents infected red blood cells from sticking to blood vessel walls, suggesting a potential target for new anti-malarial treatments.
Researchers discovered eight genes encoding proteins required for the malaria parasite to hijack and remodel human red blood cells. The proteins play a major role in the development of malaria, which kills millions of people annually. Understanding these proteins may lead to new therapeutic approaches, including drugs or live vaccines.
Recent studies in Papua and New Guinea reveal P. vivax cases, particularly in young children, are more likely to develop severe disease and experience cerebral malaria.
A recent study highlights the need for better treatments for malaria in pregnancy, where the use of new medicines is often restricted due to limited clinical data. The authors argue that this 'catch-22' situation can lead to inferior drugs being prescribed, putting pregnant women's lives at risk.
Researchers found a new enzyme, EhROM1, that helps the dysentery-causing amoeba evade the immune system. The enzyme is part of an ancient group of enzymes used by malaria parasites to enter host cells.
Maternal malaria researcher Professor François Nosten has won a prestigious international prize for his groundbreaking work on treating infections in pregnant women. His research has led to a revision of guidelines and improved treatment options for millions of people worldwide.
Scientists have disrupted malaria parasite transmission in animal tests by blocking potassium channels, preventing the formation of new infectious parasites. This breakthrough could pave the way for new anti-malaria treatments and counteracting the spread of the disease.
A new magnetic resonance imaging unit will be put into operation in Malawi, allowing physicians to assess malaria damage before a child has died and diagnose a wide range of illnesses. The machine will also enable radiologists to send images to the US for second opinions and serve neighboring countries with no MRI machines.
Research identifies PKG as essential molecule for malaria parasite's reproductive cycle. The protein is necessary for 'rounding up' transformation, allowing fertilization to occur.
Researchers have found a way to prevent malaria parasites from becoming sexually mature, a crucial step in transmission. This breakthrough could lead to the development of new drugs targeting this stage of the life cycle, helping to control the spread of drug resistance.
A University of South Florida study found that protein MAEBL is essential for malaria parasites to invade mosquito salivary glands, allowing transmission to humans. By silencing the receptor for MAEBL, researchers hope to block passage of the parasite through mosquitoes.
Researchers have created a new technique for diagnosing malaria that could be as effective as current rapid diagnostic tests but far faster and cheaper. The method uses magneto-optic technology to detect haemozoin, a waste product of the malarial parasite, in blood samples.
Researchers at Virginia Tech have identified Heme Detoxification Protein (HDP), which rapidly converts heme into its non-toxic counterpart hemozoin, protecting the malaria parasite from toxic damage. This finding presents a promising target for developing new malaria drugs.
Key findings from The Lancet report show that Ethiopia and Rwanda reduced malaria cases by 51% and 64%, deaths by 60% and 66% between 2005-2007 through expanded access to bed nets and artemisinin-based combination therapies. An ambitious campaign is proposed to expand access to malaria control interventions, targeting everyone at risk,...
Researchers at Florida State University have discovered an autoimmune-like response in the blood of malaria-infected African children that helps explain why existing DNA-based anti-malaria vaccines have repeatedly failed to protect them. The study sheds light on the unique medical needs of malaria's smallest, most vulnerable victims an...
A study by researchers at the University of Toronto found that individuals with a specific enzyme deficiency may be protected from severe and fatal malaria. The enzyme pyruvate kinase plays a crucial role in energy production and its deficiency is linked to protection against malaria infection.
The RSTMH president calls for a shift in global health priorities to address neglected tropical diseases with effective treatments available at minimal cost. Currently, billions of people lack access to quality healthcare products, hindering their well-being and productivity.
A new study questions the effectiveness of $220 million in malaria prevention efforts, citing a surge in annual mortality rates among teens and adults. The researchers call for addressing environmental factors contributing to malaria growth and developing more efficient control programs.
Researchers pooled data from 15 clinical trials to compare the efficacy of rectal artemisinins and conventional injectable antimalarials like quinine. Rectal artemisinins cleared malarial parasites more rapidly than quinine, suggesting they could be a lifesaving intervention in severe malaria cases.
Researchers from UT Southwestern Medical Center have found that the malaria parasite uses a two-step process for reproduction, which could lead to a new type of vaccine. By blocking one protein, they were able to stop the spread of the disease in mice and mosquitoes.
A Michigan State University researcher is leading a study on insecticide-treated bed nets to disrupt mosquito populations and reduce malaria transmission. The project aims to evaluate the effectiveness of bed nets over time and monitor changes in parasite populations and virulence factors.
A new study reveals that children with a mild form of alpha thalassemia have more red blood cells, which provides an advantage against life-threatening malarial anemia. This adaptation allows them to tolerate massive blood cell loss during severe malaria attacks.
Researchers developed a mathematical model estimating asymptomatic infections in malaria transmission. The model predicts that regions of moderate transmission can be eradicated below a threshold, making industrialized nations highly unlikely to experience re-emergence.
A $30 million grant will fund research to improve malaria control and treatment in pregnancy across Africa, Asia, and Latin America. The initiative aims to reduce maternal anaemia and low birth weight, potentially saving the lives of up to 100,000 children every year.
The London School of Hygiene & Tropical Medicine has been awarded grant funding to develop new treatments for malaria, tuberculosis, and HIV/AIDS. The $59 million investment will support research initiatives, including a co-ordinated programme to optimize combination drug treatment for malaria in Africa and Asia.
A new drug, JPC-2056, is 10 times more effective than the current gold-standard treatment for toxoplasmosis and has no toxicity. It inhibits the action of an enzyme produced by the parasite, making it a promising treatment option.
Researchers at ETH Zurich have developed a novel antibody test that can detect specific antibodies against Plasmodium falciparum's toxic sugar molecules. This test has the potential to protect adults from severe malaria and could also be used to develop a selective vaccine for infants under 5, who are most vulnerable to the disease.